Galderma Study Reveals 56% of Women Misattribute Menopause Skin…

Event summary

Galderma's global survey of 5,090 women found 56% initially misattributed menopause-related skin changes to aging, while only 29% linked them to menopause.
70% of women purchased anti-aging products believing they would address menopause-related skin changes.
Clinical trial data showed Restylane Skinboosters followed by Sculptra treatments improved skin hydration and quality in menopausal women.
Galderma launched a campaign to educate women about menopausal skin changes ahead of World Menopause Day (October 18, 2026).

The big picture

Galderma's findings highlight a significant gap in consumer awareness about menopause-related skin changes, positioning the company to lead in a growing niche within the dermatology market. The strategic emphasis on education and science-backed solutions aligns with broader industry trends toward personalized and preventive skin care. With a portfolio spanning injectable aesthetics and dermatological skincare, Galderma is well-positioned to capitalize on this underserved segment.

What we're watching

Market Education: Whether Galderma's campaign can effectively shift consumer perception from aging to menopause-specific skin care.
Product Differentiation: How the clinical data on treatment sequencing will position Galderma's products against competitors in the menopausal skin care market.
Regulatory Landscape: The pace at which regulatory bodies may require clearer labeling or education around menopause-related skin treatments.